Literature DB >> 6280919

Ranitidine kinetics in normal subjects.

N P Chau, P Y Zech, N Pozet, A Hadj-Aissa.   

Abstract

A 1-mg/kg IV bolus injection and a 150-mg (one tablet) oral dose of ranitidine were given to seven normal subjects. At least 1 wk separated the two doses. Ranitidine disappeared from plasma with a half-life of about 2.5 hr. Half of the oral dose was effectively absorbed and half of the absorbed amount was found unchanged in urine. Total body clearance was 10.1 ml/min/kg. Urinary clearance was the same after oral and intravenous doses (6.4 and 6.9 ml/min/kg, P greater than 0.10). Intravenous ranitidine kinetics included three phases, with a central distribution volume of 0.2 l/kg and a total distribution volume of 1.2 l/kg. Absorption kinetics were apparently order zero: of the 150-mg dose, 75 mg was absorbed during 5 hr at a constant rate of 15 mg/hr.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6280919     DOI: 10.1038/clpt.1982.109

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.

Authors:  N Inotsume; M Nishimura; S Fujiyama; K Sagara; T Sato; Y Imai; H Matsui; M Nakano
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Pharmacokinetics of ranitidine in patients undergoing haemofiltration.

Authors:  U Gladziwa; D R Krishna; U Klotz; T H Ittel; H Schunkert; W M Glöckner; H Mann
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  The effect of ranitidine and cimetidine on imipramine disposition.

Authors:  B G Wells; J A Pieper; T H Self; C F Stewart; S L Waldon; L Bobo; C Warner
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

Review 9.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 10.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.